We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Physiologic Effects of PRMS & Testosterone in the Debilitated Elderly

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00018356
Recruitment Status : Completed
First Posted : July 5, 2001
Last Update Posted : June 23, 2011
Sponsor:
Information provided by:
VA Office of Research and Development

Brief Summary:
This study's primary objective is to determine the independent and combined effects of progressive resistance muscle strength training and testosterone on the development of sustainable improvements in physical function.

Condition or disease Intervention/treatment Phase
Muscle Weakness Muscular Atrophy Procedure: exercise Drug: testosterone Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 88 participants
Official Title: Physiologic Effects of PRMS & Testosterone in the Debilitated Elderly
Study Start Date : January 1999
Primary Completion Date : July 2006
Study Completion Date : August 2006

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
1 Procedure: exercise Drug: testosterone




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   65 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

The study will be limited to those patients who are metabolically stable and free of metastatic cancer and limiting end organ disease. Their total serum testosterone must be less than 480 and PSA less than 10.

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00018356


Locations
United States, Arkansas
Central Arkansas VHS Eugene J. Towbin Healthcare Ctr, Little Rock
No. Little Rock, Arkansas, United States, 72114-1706
Sponsors and Collaborators
VA Office of Research and Development
Investigators
Principal Investigator: Dennis Sullivan, MD Central Arkansas VHS Eugene J. Towbin Healthcare Ctr, Little Rock

Publications:
Responsible Party: Sullivan, Dennis - Principal Investigator, Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT00018356     History of Changes
Other Study ID Numbers: AGCG-007-98S
First Posted: July 5, 2001    Key Record Dates
Last Update Posted: June 23, 2011
Last Verified: June 2011

Keywords provided by VA Office of Research and Development:
Aging
nutrition
rehabilitation

Additional relevant MeSH terms:
Atrophy
Muscular Atrophy
Muscle Weakness
Paresis
Pathological Conditions, Anatomical
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Muscular Diseases
Musculoskeletal Diseases
Pathologic Processes
Testosterone
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Methyltestosterone
Androgens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents